Repligen Co. (NASDAQ:RGEN) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. lessened its position in Repligen Co. (NASDAQ:RGEN) by 27.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,908 shares of the biotechnology company’s stock after selling 3,716 shares during the period. Victory Capital Management Inc.’s holdings in Repligen were worth $1,426,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Resources Management Corp CT ADV acquired a new stake in shares of Repligen in the 3rd quarter worth about $37,000. Quarry LP increased its holdings in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 239 shares during the period. UMB Bank n.a. increased its holdings in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 110 shares during the period. Global Retirement Partners LLC increased its holdings in shares of Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 129 shares during the period. Finally, GAMMA Investing LLC increased its holdings in shares of Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 90 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

RGEN has been the topic of several research analyst reports. StockNews.com cut shares of Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Canaccord Genuity Group raised their target price on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Evercore ISI initiated coverage on shares of Repligen in a research report on Tuesday. They set an “in-line” rating and a $155.00 price objective for the company. Finally, Royal Bank of Canada raised their price objective on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $178.64.

Repligen Stock Performance

RGEN stock opened at $144.34 on Wednesday. The stock has a market cap of $8.09 billion, a P/E ratio of -283.02, a P/E/G ratio of 4.54 and a beta of 0.95. The firm has a 50 day simple moving average of $156.98 and a 200 day simple moving average of $148.49. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $200.23.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.